Eversept Partners’s Jade Biosciences JBIO Stock Holding History

Eversept Partners’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,861	Closed	-$1.01M	–	68
2024 Q3	$1.01M	Buy	+13,861	New	+$894K	0.08%	64
2024 Q2	–	Sell	-1,547	Closed	-$1.6M	–	75
2024 Q1	$1.6M	Buy	1,547 +112	+8%	+$85.5K	0.12%	64
2023 Q4	$1.14M	Hold	1,435	–	–	0.11%	54
2023 Q3	$682K	Hold	1,435	–	–	0.08%	67
2023 Q2	$862K	Hold	1,435	–	–	0.09%	65
2023 Q1	$1.01M	Sell	1,435 -1,172	-45%	-$972K	0.09%	58
2022 Q4	$2.67M	Buy	+2,607	New	+$1.89M	0.25%	44

Other funds holding JBIO

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2B AUM 117.41% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Logos Global Management San Francisco, California $1.94B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.66B AUM 340.85% 1-Year Est. Return

Allostery Investments Stamford, Connecticut $7.85M AUM